help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saika, M.
Right arrow Articles by Matsumoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saika, M.
Right arrow Articles by Matsumoto, T.
Endocrinology Vol. 142, No. 6 2205-2212
Copyright © 2001 by The Endocrine Society

ARTICLES

17ß-Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor-{alpha}1

Mieko Saika, Daisuke Inoue, Shinsuke Kido and Toshio Matsumoto

First Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima, Japan

Address all correspondence and requests for reprints to: Daisuke Inoue, M.D., First Department of Internal Medicine, University of Tokushima School of Medicine, 3–18-15 Kuramoto-cho, Tokushima 770-8503, Japan. E-mail: inoued{at}clin.med.tokushima-u.ac.jp

Osteoprotegerin (OPG) is a recently identified member of the tumor necrosis factor (TNF) receptor superfamily that regulates bone mass through an inhibitory action on osteoclast differentiation and function. To determine its potential roles of OPG in pathological changes in bone metabolism caused by estrogen deficiency, we investigated effects of estrogen on OPG expression by a mouse stromal cell line, ST-2, in vitro. Treatment of ST-2 cells with 17ß-E2 resulted in up-regulation of OPG expression at both the messenger RNA and protein levels. The effect was time and dose dependent and steroid specific. The stimulatory action of 17ß-E2 on OPG expression appeared to be mediated by the estrogen receptor-{alpha} (ER{alpha}) subtype because stable overexpression of ER{alpha}, but not of ERß, enhanced the OPG induction by 17ß-E2. Moreover, estrogen withdrawal after 5-day pretreatment, mimicking the event occurring in vivo at menopause, dramatically diminished the expression of OPG. These findings suggest that down-regulation of OPG after estrogen withdrawal contributes to the enhanced osteoclastic bone resorption and bone loss after menopause by enhancing RANK ligand-RANK system that lies downstream of a large number of bone-resorbing cytokines.




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
H. F Escobar-Morreale, J. I Botella-Carretero, M. A. Martinez-Garcia, M. Luque-Ramirez, F. Alvarez-Blasco, and J. L S. Millan
Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome
Eur. J. Endocrinol., September 1, 2008; 159(3): 225 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. H. Straub
The Complex Role of Estrogens in Inflammation
Endocr. Rev., August 1, 2007; 28(5): 521 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Stern, G. A Laughlin, J. Bergstrom, and E. Barrett-Connor
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor {kappa}B legend with bone mineral density in older adults: the Rancho Bernardo Study
Eur. J. Endocrinol., May 1, 2007; 156(5): 555 - 562.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
U.H. Lerner
Bone Remodeling in Post-menopausal Osteoporosis
Journal of Dental Research, July 1, 2006; 85(7): 584 - 595.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Rogers and R. Eastell
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, K. A. Hoey, K. L. Mielke, J. D. Veldhuis, and S. Khosla
A Randomized Placebo-Controlled Trial of Short-Term Graded Transdermal Estradiol in Healthy Gonadotropin-Releasing Hormone Agonist-Suppressed Pre- and Postmenopausal Women: Effects on Serum Markers of Bone Turnover, Insulin-Like Growth Factor-I, and Osteoclastogenic Mediators
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1953 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A Martinetti, E Bajetta, L Ferrari, N Zilembo, E Seregni, M Del Vecchio, R Longarini, I La Torre, L Toffolatti, D Paleari, et al.
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole
Endocr. Relat. Cancer, December 1, 2004; 11(4): 771 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Endocr. Rev., August 1, 2004; 25(4): 629 - 672.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson
Androgens and Bone
Endocr. Rev., June 1, 2004; 25(3): 389 - 425.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F.-S. Wang, C.-J. Wang, Y.-J. Chen, Y.-T. Huang, H.-C. Huang, P.-R. Chang, Y.-C. Sun, and K. D. Yang
Nitric Oxide Donor Increases Osteoprotegerin Production and Osteoclastogenesis Inhibitory Activity in Bone Marrow Stromal Cells from Ovariectomized Rats
Endocrinology, May 1, 2004; 145(5): 2148 - 2156.
[Abstract] [Full Text] [PDF]

Home page
 CROBMHome page
U. H. Lerner
NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION
Critical Reviews in Oral Biology & Medicine, March 1, 2004; 15(2): 64 - 81.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Crisafulli, D. Altavilla, G. Squadrito, A. Romeo, E. B. Adamo, R. Marini, M. A. Inferrera, H. Marini, A. Bitto, R. D'anna, et al.
Effects of the Phytoestrogen Genistein on the Circulating Soluble Receptor Activator of Nuclear Factor {kappa}B Ligand-Osteoprotegerin System in Early Postmenopausal Women
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 188 - 192.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Viereck, C. Grundker, S. Blaschke, B. Niederkleine, H. Siggelkow, K.-H. Frosch, D. Raddatz, G. Emons, and L. C. Hofbauer
Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4206 - 4213.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D H. Jones, Y-Y Kong, and J M Penninger
Role of RANKL and RANK in bone loss and arthritis
Ann Rheum Dis, November 1, 2002; 61(90002): ii32 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Yeh, M.-Y. Tsai, Q. Xu, X.-M. Mu, H. Lardy, K.-E. Huang, H. Lin, S.-D. Yeh, S. Altuwaijri, X. Zhou, et al.
Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues
PNAS, October 15, 2002; 99(21): 13498 - 13503.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
E. Bonnelye, V. Kung, C. Laplace, D. L. Galson, and J. E. Aubin
Estrogen Receptor-Related Receptor {alpha} Impinges on the Estrogen Axis in Bone: Potential Function in Osteoporosis
Endocrinology, September 1, 2002; 143(9): 3658 - 3670.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Okazaki, D. Inoue, M. Shibata, M. Saika, S. Kido, H. Ooka, H. Tomiyama, Y. Sakamoto, and T. Matsumoto
Estrogen Promotes Early Osteoblast Differentiation and Inhibits Adipocyte Differentiation in Mouse Bone Marrow Stromal Cell Lines that Express Estrogen Receptor (ER) {alpha} or {beta}
Endocrinology, June 1, 2002; 143(6): 2349 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Khosla, E. J. Atkinson, C. R. Dunstan, and W. M. O'Fallon
Effect of Estrogen versus Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1550 - 1554.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Schoppet, K. T. Preissner, and L. C. Hofbauer
RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 549 - 553.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz
Changes in Proinflammatory Cytokine Activity after Menopause
Endocr. Rev., February 1, 2002; 23(1): 90 - 119.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Khosla
Minireview: The OPG/RANKL/RANK System
Endocrinology, December 1, 2001; 142(12): 5050 - 5055.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Schoppet, K. T. Preissner, and L. C. Hofbauer
RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 549 - 553.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society